Lynx Posts Sharp Drop in Revenues, Stable Losses for Q1 | GenomeWeb

NEW YORK, May 14 (GenomeWeb News) - Lynx Therapeutics yesterday reported sharply declined revenues and stable losses for the first quarter of the year.


Revenues totaled $1.3 million, down from $3.3 million during the first quarter of last year.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.